By Diwakar Sinha

If you spend enough time around healthcare M&A, you hear a familiar story.

“I didn’t know my equity worked that way.”

“I didn’t realize I could be diluted.”

“I thought there would be another liquidity event.”

“I didn’t understand what would happen at the next recap.”

And sometimes, those stories are followed by frustration with the buyer, the DSO/MSO, the private equity firm, or the transaction itself. But here’s the uncomfortable part: sometimes the problem wasn’t the deal. It was entering a sophisticated transaction without sophisticated representation.

That’s not about blaming the seller. It’s about recognizing something every healthcare owner considering a transaction deserves to understand: who represents you, and how well they represent you, can materially affect what happens long after the deal closes.

I’ve seen groups receive similar valuations and have vastly different results years later. Not because one negotiated another half turn on the multiple, but because one better understood and negotiated the structure around it. The purchase price is only one component of the outcome.

Looking Beyond the Multiple

When a transaction is announced, the first question is typically, “What multiple did they receive?” While understandable, it is rarely the only question that matters.

A more meaningful discussion includes:

How much rollover equity was retained? Where does that equity sit in the capital structure? What rights and protections accompany ownership? How is future dilution handled? What opportunities exist for future liquidity? How will future acquisitions impact value creation? What incentives exist for doctors and key operators to remain aligned?

And perhaps most importantly: How do you actually monetize the second bite of the apple?

These factors may not generate headlines, but they can have a significant impact on long-term outcomes.

The Same Valuation, Different Result

Consider two doctor-owned groups that both sell at the same EBITDA multiple. On paper, the transactions may appear nearly identical. Yet several years later, one group may have meaningfully increased its wealth through retained equity and a successful recapitalization, while another may find its rollover investment never performed as expected.

What created the difference?

Often, it comes down to structure, alignment, and the details negotiated throughout the process. That raises another question owners need to consider: Who was sitting on their side of the table?

The Cost of Going It Alone

I understand why owners sometimes hesitate to hire an advisor. When you’ve spent years building a successful organization, it’s reasonable to wonder whether you can navigate a transaction yourself and avoid that expense. But avoiding an advisory fee can become very expensive if it means leaving value on the table, accepting unfavorable terms, misunderstanding rollover equity, or failing to negotiate protections that matter years after closing.

Healthcare buyers and investors do transactions for a living. Most healthcare owners don’t. It’s simply the reality of the negotiating table.

This isn’t about saying Polaris Healthcare Partners is the only answer. It’s about making sure you have sophisticated representation from someone who understands the economics, structure and long-term implications of the transaction, and whose job is to represent your interests.

I’ve had too many conversations with owners after the fact who say, “I didn’t know.” And every time, I’m reminded of exactly why experienced representation matters.

Understanding Rollover Equity

Few aspects of healthcare transactions generate more discussion than rollover equity. Some sellers see it as an opportunity. Others see it as a risk. In reality, it can be both.

The critical issue is not whether rollover equity exists. The critical issue is understanding its economics, governance, liquidity options, and role within the broader transaction.

Well-structured rollover equity can create substantial value if growth objectives are achieved, and future liquidity events occur. Conversely, equity that is poorly understood or improperly positioned can leave owners frustrated regardless of the price received at closing.

The difference lies in understanding exactly what is being retained, how it participates in future growth, what risks accompany it, and how value may ultimately be realized.

Sophisticated Transactions Require Sophisticated Planning

Healthcare transactions have evolved considerably over the last decade. Today’s deals involve complex considerations around capital structures, lender requirements, growth expectations, operational integration, physician alignment, and future acquisition strategies.

Sellers should evaluate transactions through the same sophisticated lens. The question should not simply be, “What is the highest offer?” It should also be: Which partner is best positioned to achieve our objectives? How do we maximize both current liquidity and future upside? What risks are we retaining? What value drivers exist after closing? How does this transaction fit into our long-term personal and professional goals?

Those questions lead to better-informed decisions about not just the transaction at closing, but what ownership may look like years afterward.

Wealth Creation Doesn’t End at Closing

One of the biggest misconceptions in healthcare M&A is that value creation ends when the transaction closes.

In reality, many meaningful economic outcomes occur after the closing table. Future growth, doctor retention, acquisition execution, operational improvement and recapitalization events can all have a material impact on ultimate shareholder returns.

That’s why owners need to understand not only what they are receiving today, but what they are retaining for tomorrow. The multiple matters. The cash at close matters. But so do the equity structure, governance rights, dilution provisions, future liquidity opportunities and the partner responsible for helping create that future value.

Final Thoughts

It’s easy to criticize a transaction after the fact. It’s harder, and far more valuable, to ask the difficult questions before you sign.

Understand the valuation. Understand the equity. Understand the dilution provisions, governance, liquidity opportunities and what happens at the next recap. And make sure you have someone at the table who understands them just as well as the people sitting across from you.

The goal isn’t simply to get a good deal at closing. It’s to understand the deal you’re actually getting, and what it could mean for you years from now.

Because when an owner tells me, “I didn’t know,” my first thought is always the same: You deserved to know before you signed.

Stay Connected